Human Microbiome Market, by Product Type (Foods (Probiotics, Prebiotics, and Medical Foods), Fecal Microbiota Transplant (FMT), Microbiome Drugs, and Others), by Disease Indication (Clostridium Difficile Infection (CDI), Inflammatory Bowel Disease (IBD),

Human Microbiome Market, by Product Type (Foods (Probiotics, Prebiotics, and Medical Foods), Fecal Microbiota Transplant (FMT), Microbiome Drugs, and Others), by Disease Indication (Clostridium Difficile Infection (CDI), Inflammatory Bowel Disease (IBD), Metabolic Disorders, Autoimmune Disorders, Allergic Diseases, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

According to the National Center for Biotechnology (NCBI), the human microbiota consists of 10-100 trillion symbiotic microbial cells, which is harbored by each person, this primarily includes bacteria in the gut. The human microbiome consists of the genes these microbial cells harbor. Microbiome projects worldwide have been launched with the goal of understanding the roles that these microbes play and their impacts on human health. They are being studied for the treatment of diseases such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal disorders, central nervous system disorders, and others.
Market Dynamics
Increasing incidence rate of various gut disorders (inflammatory bowel disease (IBD), Crohn’s disease etc.) is expected to increase the growth of the global human microbiome market over the forecast period. For instance, according to a study published in Lancet in October 2019, around 319 (U.S.) cases and around 322 (Europe) cases of Crohn’s disease were reported per 100,000 people. As per the Centers for Disease Control and Prevention’s (CDC) 2018 statistics, an estimated 1.3% of the U.S. adults (accounting for 3 million individuals) were diagnosed with IBD (either Crohn’s disease or ulcerative colitis) in 2015. This showcased a major increase in the incidence rate of IBD from 1999, when 0.9% of the U.S. adults (2 million) were diagnosed with IBD.
Market players are involved in inorganic activities such as collaborations for research and development activities. This is expected to increase the growth of the market over the forecast period. For instance, in 2017, Second Genome, Inc., collaborated with the research institutes i.e., Stanford Cancer Institute, Ruprecht-Karl's-University Heidelberg, Roswell Park Comprehensive Cancer Center, and John Theurer Cancer Center in order to evaluate the effect of gut microbiota on individual response to cancer immunotherapies.
Key features of the study:
This report provides an in-depth analysis of global human microbiome market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global human microbiome market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global human microbiome market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the human microbiome market
Detailed Segmentation:
Global Human Microbiome Market, By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
Global Human Microbiome Market, By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
Global Human Microbiome Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Human Microbiome Market, By Region:
North America
By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
By Disease Indication:
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
ENTEROME SA*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Embion Technologies S.A
IGEN BIOLAB GROUP
Evelo Biosciences Inc
Ferring Pharmaceuticals
4D Pharma Plc
Gnubiotics Sciences
YSOPIA Bioscience
ViThera Pharmaceuticals Inc.
SECOND GENOME THERAPEUTICS
Osel Inc.
OxThera AB
Immuron Ltd.
AOBiome
Vedanta Biosciences, Inc.
Rebiotix Inc.
Seres Therapeutics, Inc.
Assembly Biosciences, Inc.
Finch Therapeutics Group, Inc.
“*” marked represents similar segmentation in other categories in the respective section.